TrialSignal transduction and targeted therapy2025

First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II randomized study.

Ru Jia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.